Placebo to omarigliptin
Sponsors
Merck Sharp & Dohme LLC
Conditions
Diabetes MellitusType 2 DiabetesType 2 Diabetes Mellitus
Phase 2
Phase 3
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
CompletedNCT01682759
Start: 2012-09-10End: 2015-01-26Updated: 2018-09-07
A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
CompletedNCT01698775
Start: 2012-10-02End: 2016-01-19Updated: 2018-08-09
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
CompletedNCT01703221
Start: 2012-10-24End: 2014-04-25Updated: 2019-08-28
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
CompletedNCT01717313
Start: 2012-12-05End: 2015-06-19Updated: 2018-09-10
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
CompletedNCT01814748
Start: 2013-05-03End: 2015-09-14Updated: 2018-09-10
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
CompletedNCT01841697
Start: 2013-06-13End: 2014-11-17Updated: 2018-09-10